Partner With Us
Fueling the translation of our RNA platform
Ronald C. Renaud, Jr.
Chief Executive Officer
×
Ronald C. Renaud, Jr.
Chief Executive Officer
Ron has served as our chief executive officer since 2014. Formerly, Ron was at Idenix Pharmaceuticals (2007-2014), where he served as chief financial officer, chief business officer and finally, president and chief executive officer. Under his leadership, Idenix refocused its drug-discovery and development efforts and streamlined operations to better enable cross-functional collaboration and employee engagement, which culminated in its acquisition by Merck for $3.85 billion in August 2014. Prior to joining Idenix, Ron served as senior vice president and chief financial officer of Keryx Biopharmaceuticals. Before joining Keryx, Ron was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Ron holds a BA from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California. In addition to serving on the Translate Bio board of directors, Ron is a board member of Akebia Therapeutics, Chimerix and Axial Biotherapeutics. Ron also serves on the Board of Overseers at Newton-Wellesley Hospital and the Board of Trustees at Saint Anselm College.
Thomas McCauley, Ph.D.
Chief Scientific Officer
×
Thomas McCauley, Ph.D.
Chief Scientific Officer
Tom has served as our chief scientific officer since 2016. Formerly, Tom served as vice president and head of global nonclinical development at Shire Pharmaceuticals. In this role, Tom was responsible for leadership of the global nonclinical and bioanalytical development departments, including pharmacology, metabolism and pharmacokinetics, toxicology, and clinical and nonclinical bioanalytical and biomarker development groups. He made significant contributions to the development and global approvals of many of Shire’s products, including Replagal® for Fabry disease, Vpriv® for Gaucher disease, Elaprase® for Hunter syndrome, Firazyr® for hereditary angioedema and Xiidra for dry eye disease. Prior to joining Shire, Tom was head of nonclinical development and clinical pharmacology and pharmacokinetics at Inotek Pharmaceuticals Corp. and was a founding scientist and group leader for nonclinical and clinical drug metabolism and pharmacokinetics at Archemix Corp. In addition to his current focus developing novel therapeutics for rare diseases, Tom has over 17 years of experience in the biotechnology and pharmaceutical industries in preclinical and clinical discovery and development of biologic and small molecule drugs for indications in cardiovascular disease, hematology, oncology, inflammation and ophthalmology. He has authored more than 40 scientific publications, book chapters and patents. He holds undergraduate and graduate degrees from Cornell University and received his PhD from the University of Alabama at Birmingham.
Michael Heartlein, Ph.D.
Chief Technical Officer
×
Michael Heartlein, Ph.D.
Chief Technical Officer
Michael Heartlein joined as our chief technical officer in 2018. He has been in research and development since 1989, when he joined the founding team of scientists at TKT (Shire acquired TKT in 2005). Prior to his current role, Mike was head of messenger RNA therapeutics at Shire. Mike’s career in R&D has focused on the discovery and development of platform technologies, product discovery and product development. He began with the development of nonviral ex-vivo gene therapy and is an inventor on 16 issued U.S. patents covering this technology. Mike also co-invented and developed Gene Activation technology, FGE-sulfatase technology and Shire’s human cell protein production platform. He discovered and developed gene-activated erythropoietin (Dynepo®), the first human cell–produced erythropoietin, approved in Europe in 2002. Mike discovered and led early development of Shire’s enzyme replacement therapies for Fabry disease (Replagal®) and Gaucher disease (Vpriv®) and early development of Elaprase® for Hunter syndrome. He also led the teams responsible for the discovery and nonclinical development of Shire’s intrathecal CNS enzyme replacement therapies currently in clinical development. Most recently, Mike discovered and developed Shire's Messenger RNA Therapy (MRT) technology acquired by Translate Bio (formerly RaNA Therapeutics). Prior to joining Shire, Mike held a hospital appointment in genetics at Children's Hospital Boston and a faculty appointment in pediatrics at Harvard Medical School. Mike received his PhD in Genetics from Oak Ridge National Laboratory – University of Tennessee. He has over 30 scientific publications, 39 issued US patents and over 60 pending US patent applications.
Brian Fenton, M.S., MBA
Chief Business Officer
×
Brian Fenton, M.S., MBA
Chief Business Officer
Brian Fenton joined the Translate Bio team in 2015. With more than 25 years of experience in the biotechnology industry and broad transaction experience in business development and alliance management, Brian joined Translate Bio from Shire Pharmaceuticals, where he most recently served as head of business development, neuroscience, supporting the Commercial Business Unit. In this role, he was also responsible for managing Shire’s portfolio investments through its former Strategic Investments Group. Brian also spent several years in Shire’s Rare Diseases Business Development group, where he successfully led and executed a number of strategic transactions for the company. Prior to Shire, Brian spent over 11 years in various roles in business development and alliance management at Idenix Pharmaceuticals, Codexis and Abbott Laboratories. He has been a co-chair for over 20 years with MassBio, serving on several committees, and most recently served on the organization’s Forum Advisory Board. Brian has an undergraduate degree in biochemistry from the University of Massachusetts/Amherst, an MS in chemical engineering from the University of Virginia and an MBA from the Worcester Polytechnic Institute.
Paul Burgess, J.D.
General Counsel
×
Paul Burgess, J.D.
General Counsel
Paul began serving as Translate Bio’s general counsel in 2016. He brings over 20 years of experience in the biotech and pharmaceutical industry, with expertise in corporate law, licensing and intellectual property. Prior to joining the Translate team, Paul held senior legal roles at Scholar Rock, Civitas Therapeutics and BIND Therapeutics. He also worked as in-house counsel at Johnson & Johnson, Logical Therapeutics and Transform Pharmaceuticals. Prior to becoming a lawyer, Paul worked as a scientist at Genetics Institute. He received his JD from Northeastern University, MS in pharmacology from Northeastern University and BS in biology from Merrimack College.
Paula Cloghessy, SPHR, SHRM-SCP
Senior Vice President, Human Resources
×
Paula Cloghessy, SPHR, SHRM-SCP
Senior Vice President, Human Resources
Paula has served as Translate Bio’s senior vice president, human resources, since 2016 and is responsible for leading human resources and organizational development. With over 20 years of experience as a human resources leader driving aggressive organizational strategy, growth and innovation, Paula brings broad-based business experience in biotech and pharmaceutical industries to her role on the Translate team. Paula joined us from Joule Unlimited Technologies, Inc., where she most recently served as vice president, human resources. In this role, she was responsible for leading Joule’s people strategy and talent architecture in a global setting. Prior to Joule, she held senior HR leadership roles at Interleukin Genetics, NUCRYST Pharmaceuticals and the Immune Disease Institute (formerly CBR Institute for Biomedical Research), a Harvard Medical School affiliate. Paula holds a BA in psychology from the University of Massachusetts and professional designations in the field of human resources.Daniel Lynch
Chairman of the Board
Read full bio »
×
Daniel Lynch
Chairman of the Board
Dan joined our board of directors in 2012 with more than 25 years of experience serving in management positions in the biotechnology and pharmaceutical industries. Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, Dan led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX® (Cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, Dan served in various financial positions at Bristol-Myers Squibb over a 15-year tenure.
Dan has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, including Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012); Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012); Nimbus Discovery, LLC; Edimer Pharmaceuticals; Ember Therapeutics, Inc. and BIND Therapeutics Inc. He currently serves on the board of directors of Blueprint Medicines, Bluebird Bio, Proclara Biosciences, Surface Oncology and Eleven Biotherapeutics, Inc. Dan received his BA in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Jean-François Formela, M.D.
Atlas Venture and Translate Bio Cofounder
Read full bio »
×
Jean-François Formela, M.D.
Atlas Venture and Translate Bio Cofounder
Jean-François is a partner and cofounder and focuses on new advances in biology and drug-discovery technologies as well as novel therapeutics. He joined our board of directors in 2011. Jean-Francois is also chair of the board of IFM Therapeutics and serves on the boards of F-star, Intellia Therapeutics (NASDAQ: NTLA), Kyn Therapeutics, Spero Therapeutics.
Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).
Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his MD from Paris University School of Medicine, and his MBA from Columbia University.
Brian M. Gallagher, Jr., Ph.D.
SR One
Read full bio »
×
Brian M. Gallagher, Jr., Ph.D.
SR One
Brian joined our board of directors in 2011 and is a partner at SR One Ltd. He established the SR One Boston office in 2010 and is focused on building innovative therapeutic and life science companies. He currently represents SR One on the boards of Aileron Therapeutics, CalciMedica, Constellation Pharmaceuticals, Navitor Pharmaceuticals, Nimbus Discovery, Translate Bio and River Vision. He previously led the firm’s investments in Dicerna Pharmaceuticals and SpringLeaf Therapeutics.
Brian has nearly 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development, operations and post-merger integration following the $720 million acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian was with Alantos Pharmaceuticals, where he played key roles in the R&D and business development activities and led many aspects of the post-merger integration following the $300 million acquisition of Alantos by Amgen in 2007. He began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas.
Brian is an inventor on over 25 patents and patent applications and is the senior author of a number of scientific publications. He currently serves on the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society, as a mentor for MassBio’s MassCONNECT, and as a peer reviewer/editorial board member for numerous journals and research funding authorities. Brian received his MS and PhD degrees in organic chemistry from the University of Michigan and his BS in chemistry from the University of Massachusetts, where he was a Shapiro scholar.
Owen Hughes
Independent Director
Read full bio »
×
Owen Hughes
Independent Director
Owen Hughes currently serves as the chief executive officer at Cullinan Oncology focused on oncological drug development. Prior to Cullinan, Mr. Hughes was the chief business officer and head of corporate development at Intarcia Therapeutics. Mr Hughes also served as director at Bain Capital Public Equity, a multibillion-dollar hedge fund. There, he comanaged public and private healthcare investments, including those in the biopharmaceutical, medtech and services segments. Mr. Hughes has over 16 years of Wall Street experience on both the buy and sell sides and serves on the board of both Radius Health (Nasdaq: RDUS) and Malin PLC (ESM: MLC).
Daniella Beckman
Chairperson of the Audit Committee
Read full bio »
×
Daniella Beckman
Chairperson of the Audit Committee
Daniella Beckman joined Translate Bio's board of directors in 2017 and also serves as chairperson of the board’s audit committee. Ms. Beckman has over 15 years of financial and operational experience working with private and publicly traded biotechnology companies. She currently provides consulting and interim chief financial officer services for early-stage biotechnology companies, which recently has included Tango Therapeutics and Neon Therapeutics. With strategic and operational expertise, Ms. Beckman focuses on building financial infrastructure and leading financial functions, including strategic financial planning. Previously, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. At Idenix, she oversaw finance, treasury, capital raises, investor relations and IT. Prior to the CFO role, Ms. Beckman also served as Idenix’s corporate controller. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Ms. Beckman holds a B.A. in business administration/accounting from Boston University. She is also a certified public accountant in Massachusetts.Ronald C. Renaud, Jr.
Chief Executive Officer
Read full bio »
×
Ronald C. Renaud, Jr.
Chief Executive Officer
Ron has served as our chief executive officer since 2014. Formerly, Ron was at Idenix Pharmaceuticals (2007-2014), where he served as chief financial officer, chief business officer and finally, president and chief executive officer. Under his leadership, Idenix refocused its drug-discovery and development efforts and streamlined operations to better enable cross-functional collaboration and employee engagement, which culminated in its acquisition by Merck for $3.85 billion in August 2014. Prior to joining Idenix, Ron served as senior vice president and chief financial officer of Keryx Biopharmaceuticals. Before joining Keryx, Ron was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Ron holds a BA from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California. In addition to serving on the Translate Bio board of directors, Ron is a board member of Akebia Therapeutics, Chimerix and Axial Biotherapeutics. Ron also serves on the Board of Overseers at Newton-Wellesley Hospital and the Board of Trustees at Saint Anselm College.
Jeannie T. Lee, MD, Ph.D., Cofounder
Read full bio »
×
Jeannie T. Lee, MD, Ph.D., Cofounder
Jeannie T. Lee is the scientific founder of Translate Bio. She is currently an investigator of the Howard Hughes Medical Institute and professor of genetics (and pathology) at Harvard Medical School and Massachusetts General Hospital (MGH). Dr. Lee specializes in the study of epigenetic regulation by long noncoding RNAs (lncRNA). Using X-chromosome inactivation (XCI) as a model, her laboratory has made several contributions to our understanding of RNA-directed chromatin change, including the role of RNA in targeting polycomb complexes and the mechanisms of repression by antisense RNA. She received her A.B. in biochemistry and molecular biology from Harvard University, where she worked on antisense repression of transposition with Nancy Kleckner. She obtained an MD-PhD degree from the University of Pennsylvania School of Medicine, where she studied epigenetic regulation of X-linked diseases with Robert L. Nussbaum. At the Whitehead Institute/MIT, her postdoctoral work with Rudolf Jaenisch delineated the X-inactivation center. She has served as chief resident of clinical pathology at MGH and received both the Basil O’Connor Scholar Award (March of Dimes) and the Pew Scholars Award (Pew Foundation) as a young investigator.
Dr. Lee has been awarded a Distinguished Graduate Award from the University of Pennsylvania School of Medicine and currently holds a MERIT Award from the NIH. She is also the recipient of the 2010 Molecular Biology Prize from the National Academy of Sciences, USA; is a fellow of the American Association for the Advancement of Science (AAAS) and serves on the board of directors for the Genetics Society of America.
Daniel Anderson, Ph.D.
Read full bio »
×
Daniel Anderson, Ph.D.
Daniel Anderson is the Sam Goldblith Associate Professor at the Massachusetts Institute of Technology (MIT). He is appointed in chemical engineering, the Institute for Medical Engineering and Science, and the Harvard-MIT Division of Health Science and Technology. He is an intramural member of the Koch Institute for Integrative Cancer Research at MIT.
Daniel’s lab’s research is centered on developing new materials for medicine. He has pioneered the use of robotic methods for the development of smart biomaterials for drug delivery and tissue engineering. In particular, his work has enabled the rapid synthesis, formulation, analysis and biological testing of large libraries of biomaterials for use in medical devices, cell therapy and drug delivery. The advanced drug delivery systems developed in his laboratory have provided new methods for nanoparticulate and microparticulate drug delivery, non-viral gene therapy, siRNA delivery and vaccines.
Daniel received a B.A. in math and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. He has published more than 230 papers, patents and patent applications. These patents have led to a number of licenses to pharmaceutical, chemical and biotechnology companies.